Recce Pharmaceuticals Ltd - ROE
RECEF
Price:
$0.22
Market Cap:
$138.81M
Recce Pharmaceuticals Ltd is a biotechnology firm dedicated to the discovery, development, and commercialization of cutting-edge synthetic anti-infective treatments. The company's operations span major markets, including Australia, the United States, and the United Kingdom. Its primary drug candidate, RECCE 327, is engineered to combat severe blood infections and sepsis caused by E. coli and S. aureus bacteria, critically, even their antibiotic-resistant 'superbug' forms. In addition to RECCE 327, the company's pipeline includes RECCE 529, another synthetic anti-infective being developed for viral infections, and RECCE 435, a synthetic polymer anti-infective. Founded in 2007, the company ori...[Read more]
Industry
Biotechnology
IPO Date
2022-08-12
Stock Exchange
OTC
Ticker
RECEF
PE Ratio
[-3.67]
ROE
[279.21%]
Current Ratio
[0.08]
Dividend Yield
[0%]
Enterprise Value
[149.70M]
Dividend History
The ROE as of June 2026 (TTM) for Recce Pharmaceuticals Ltd (RECEF) is 279.21%
According to Recce Pharmaceuticals Ltd’s latest financial reports and current stock price. The company's current ROE is 279.21%. This represents a change of 39.64% compared to the average of 199.95% of the last 4 quarters.
Recce Pharmaceuticals Ltd (RECEF) Historical ROE (quarterly & annually)
How has RECEF ROE performed in the past?
The mean historical ROE of Recce Pharmaceuticals Ltd over the last ten years is 82.72%. The current 279.21% ROE has changed 237.52% with respect to the historical average. Over the past ten years (40 quarters), RECEF's ROE was at its highest in in the June 2025 quarter at 448.65%. The ROE was at its lowest in in the December 2023 quarter at -1396.87%.
Average
82.72%
Median
-87.55%
Minimum
-512.67%
Maximum
702.10%
Recce Pharmaceuticals Ltd (RECEF) ROE by Quarter and Year
Discovering the peaks and valleys of Recce Pharmaceuticals Ltd ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.34%
Maximum Annual ROE = 702.10%
Minimum Annual Increase = -562.62%
Minimum Annual ROE = -512.67%
| Year | ROE | Change |
|---|---|---|
| 2025 | 702.10% | 278.59% |
| 2024 | 185.45% | -63.29% |
| 2023 | 505.15% | -562.62% |
| 2022 | -109.19% | 65.68% |
| 2021 | -65.91% | -64.69% |
| 2020 | -186.66% | -127.14% |
| 2019 | 687.67% | -385.42% |
| 2018 | -240.93% | -53.00% |
| 2017 | -512.67% | 272.17% |
| 2016 | -137.75% | 1.34% |
Recce Pharmaceuticals Ltd (RECEF) Average ROE
How has RECEF ROE performed in the past?
The current ROE of Recce Pharmaceuticals Ltd (RECEF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
464.23%
5-year avg
243.52%
10-year avg
82.72%
Recce Pharmaceuticals Ltd (RECEF) ROE vs. Peers
How is RECEF’s ROE compared to its peers?
Recce Pharmaceuticals Ltd’s ROE is greater than Adocia S.A. (-3796.57%), less than Faron Pharmaceuticals Oy (45.13%), greater than AnGes, Inc. (-156.47%), greater than Broncus Holding Corporation (-11.54%), less than EKF Diagnostics Holdings plc (3.01%), greater than Eupraxia Pharmaceuticals Inc. (-50.81%), less than ACS Global, Inc. (0%), greater than Prescient Therapeutics Limited (-62.49%), greater than Adocia S.A. (-3796.57%), greater than Planet 13 Holdings Inc. (-112.30%),
| Company | ROE | Market cap |
|---|---|---|
| -3796.57% | $170.44M | |
| 45.13% | $209.54M | |
| -156.47% | $142.50M | |
| -11.54% | $42.13M | |
| 3.01% | $149.28M | |
| -50.81% | $108.29M | |
| 0% | $171.27M | |
| -62.49% | $117.53M | |
| -3796.57% | $103.66M | |
| -112.30% | $202.02M |
Build a custom stock screener for Recce Pharmaceuticals Ltd (RECEF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Recce Pharmaceuticals Ltd using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Recce Pharmaceuticals Ltd (RECEF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Recce Pharmaceuticals Ltd or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Recce Pharmaceuticals Ltd's ROE?
How is the ROE calculated for Recce Pharmaceuticals Ltd (RECEF)?
What is the highest ROE for Recce Pharmaceuticals Ltd (RECEF)?
What is the 3-year average ROE for Recce Pharmaceuticals Ltd (RECEF)?
What is the 5-year average ROE for Recce Pharmaceuticals Ltd (RECEF)?
How does the current ROE for Recce Pharmaceuticals Ltd (RECEF) compare to its historical average?